Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04889716 · ClinicalTrials.gov registry record · Phase 2
CAR-T Followed by Bispecific Antibodies
A Phase 2 study of Large B-cell Lymphoma and DLBCL - Diffuse Large B Cell Lymphoma, sponsored by Abramson Cancer Center at Penn Medicine.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
- 2
- Study locations
NCT04889716 is a Phase 2 study of Large B-cell Lymphoma and DLBCL - Diffuse Large B Cell Lymphoma that is actively recruiting participants, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 42 participants, below the 157-participant average among 28 other Large B-cell Lymphoma trials with a reported enrollment target (73% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT04889716, a Phase 2 study of Large B-cell Lymphoma and DLBCL - Diffuse Large B Cell Lymphoma, is actively recruiting participants, sponsored by Abramson Cancer Center at Penn Medicine.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
- 2
- Study locations
Study Summary
The research study is being conducted to test the safety and effectiveness of the experimental drug mosunetuzumab (Cohort 1) or obinutuzumab and glofitamab (Cohort 2) when given after CAR (genetically modified) T cells. The study is for patients who have already received a CAR T-cell infusion. Some patients who join the study will receive mosunetuzumab, other patients later in the study may receive a different experimental drug (glofitamab, in combination with obinutuzumab).
Conditions Studied
Interventions
- DRUG mosunetuzumab
- DRUG glofitamab
- DRUG obinutuzumab
Study Locations (2)
Nebraska
- University of Nebraska Medical Center - Omaha
Pennsylvania
- Abramson Cancer Center of the University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2021-11-05 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04889716
The ClinicalTrials.gov registry entry for NCT04889716 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 157-participant average among 28 other Large B-cell Lymphoma trials with a reported enrollment target (73% lower). The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Large B-cell Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which mosunetuzumab is the first listed.
NCT04889716 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Nebraska, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04889716 about?
NCT04889716 is a clinical study titled "CAR-T Followed by Bispecific Antibodies". The research study is being conducted to test the safety and effectiveness of the experimental drug mosunetuzumab (Cohort 1) or obinutuzumab and glofitamab (Cohort 2) when given after CAR (genetically modified) T cells. The study is for patients who have already received a CAR T-cell infusion. Some ...
What is the current status of trial NCT04889716?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2021-11-05. Estimated completion is 2028-12-31.
What conditions does trial NCT04889716 study?
This clinical trial studies the following conditions: Large B-cell Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma.
What interventions are being tested in trial NCT04889716?
The interventions under investigation include: mosunetuzumab (DRUG), glofitamab (DRUG), obinutuzumab (DRUG).
Who is sponsoring clinical trial NCT04889716?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04889716 being conducted?
This trial has 2 study locations across Nebraska, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Large B-cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
RECRUITING · Phase 2
-
Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma
RECRUITING · Phase 2
-
Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym
RECRUITING · Phase 2
-
Emapalumab Prevention of CAR-T Cell Associated Toxicities
RECRUITING · Phase 2
-
Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.